Mizuho Maintains Buy on Inspire Medical Systems, Maintains $250 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone reaffirmed a Buy rating on Inspire Medical Systems (NYSE:INSP) and maintained a $250 price target on the stock.
March 27, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Anthony Petrone reaffirmed a Buy rating on Inspire Medical Systems with a $250 price target.
The reaffirmation of a Buy rating and a high price target by a reputable analyst like Anthony Petrone from Mizuho is likely to instill confidence among investors and could lead to a positive short-term impact on INSP's stock price. Analyst ratings, especially with a high price target, often signal market confidence in the company's future performance, potentially influencing investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100